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Presenilin mutations are responsible for most cases of
autosomal dominant inherited forms of early onset Al-
zheimer disease. Presenilins play an important role in
amyloid -precursor processing, NOTCH receptor sig-
naling, and apoptosis. However, the molecular mecha-
nisms by which presenilins regulate apoptosis are not
fully understood. Here, we report that presenilin-1 (PS1)
regulates the proteolytic activity of the serine protease
Omi/HtrA2 through direct interaction with its regula-
tory PDZ domain. We show that a peptide corresponding
to the cytoplasmic C-terminal tail of PS1 dramatically
increases the proteolytic activity of Omi/HtrA2 toward
the inhibitor of apoptosis proteins and -casein and in-
duces cell death in an Omi/HtrA2-dependent manner.
Consistent with these results, ectopic expression of full-
length PS1, but not PS1 lacking the C-terminal PDZ
binding motif, potentiated Omi/HtrA2-induced cell
death. Our results suggest that the C terminus of PS1 is
an activation peptide ligand for the PDZ domain of Omi/
HtrA2 and may regulate the protease activity of Omi/
HtrA2 after its release from the mitochondria during
apoptosis. This mechanism of Omi/HtrA2 activation is
similar to the mechanism of activation of the related
bacterial DegS protease by the outer-membrane porins.
The presenilin proteins, presenilin-1 (PS1)1 and presenilin-2
(PS2), have been implicated in the etiology of Alzheimer dis-
ease (AD) in humans (1–3). Mutations in the PS1 gene are
responsible for about 60% of familial early-onset AD cases (4).
Presenilins are highly conserved in evolution, being present
also in Caenorhabditis elegans and Drosophila melanogaster,
and are transcribed in many different cell types, both within
the central nervous system and in peripheral tissues.
PS1 is a polytopic integral membrane protein composed of
eight hydrophobic transmembrane (TM) segments, with N-
terminal and C-terminal tails facing the cytoplasm. It is be-
lieved to be a catalytic subunit of a stable, high molecular mass
-secretase complex, which contains also the three essential
cofactors nicastrin, anterior pharynx defective 1, and preseni-
lin enhancer 2 (5). In this complex the PS1 holoprotein (44
kDa) undergoes constitutive endoproteolytic processing be-
tween TM6 and TM7 and, therefore, exists as a stable het-
erodimer composed of N-terminal fragment and C-terminal
fragment (6). The presenilin-dependent -secretase activity is
responsible for the proteolytic cleavage of the amyloid precur-
sor protein, the NOTCH receptor protein, and several other
substrates, including ErbB4, LRP, CD44, E-Cadherin, Nectin-
1, APLP-1, and Ire1 (7). PS1 interacts physically and func-
tionally with proteins that are involved in a wide array of
cellular functions. In particular, the C terminus of PS1 has
been shown to interact with proteins such as PSAP, X11,
X11, PAMP, and PARL but physiological function of these
interactions is unknown (8–10).
Omi/HtrA2 is a serine protease that belongs to the high
temperature requirement A (HtrA) protease family (11, 12). It
is synthesized as a precursor protein and then targeted to the
mitochondria where it is matured by the removal of N-terminal
133 residues. Recent studies have implicated Omi/HtrA2 in the
process of apoptosis (13–16). The mature Omi/HtrA2 carries an
IAP binding motif at its N terminus in addition to the serine
protease domain. Following apoptotic stimuli, Omi/HtrA2 is
released to the cytoplasm where it interacts with X-chromo-
some-linked inhibitor of apoptosis protein (XIAP) and relieves
its inhibition of caspase-9 (13–16). In addition, Omi/HtrA2 can
promote apoptosis in a caspase-independent mechanism
through its ability to cleave IAPs in the cytoplasm (17–19).
In addition to its role in apoptosis we have recently shown
that Omi/HtrA2 has a vital role in the mitochondria. Themnd2
(motor neuron degeneration 2) mutant mice suffer from a neu-
rodegenerative disease that causes muscle wasting and death
by 6 weeks of age as a result of a point mutation in a noncata-
lytic serine residue (S276C) in the Omi/HtrA2 protein (20). The
mutation does not affect the processing or localization of the
mutant Omi/HtrA2 protein but renders it proteolytically inac-
tive. The loss of Omi/HtrA2 protease activity increases the
susceptibility of mitochondria to induction of the permeability
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transition and increases the sensitivity of mouse embryonic
fibroblasts to stress-induced cell death.
A defining feature of the HtrA protease family is the combi-
nation of a catalytic serine-protease domain with at least one
PDZ domain (12, 21, 22). The PDZ domains are small globular
domains that act as protein-protein recognition modules and
are involved in many signaling cascades (12, 21, 22). They are
named after the three proteins where they were originally
found: postsynaptic density protein-95 (PSD-95) (23), Drosoph-
ila discs large tumor suppressor (Dlg) (24), and the tight junc-
tion protein (ZO-1) (25). The PDZ domains are defined by a
unique sequence of 80–100 amino acids able to recognize spe-
cific C-terminal sequences in target proteins (26, 27). Recent
structural and biochemical evidence suggested that the PDZ
domain in the bacterial HtrA protease DegS modulates the
activity of the protease domain upon binding to specific activa-
tion peptides derived from the C termini of the OMP proteins
(28, 29). Here we report that peptides derived from the C
termini of human Presenilins modulate the protease and apo-
ptotic activities of Omi/HtrA2 by binding to its PDZ domain.
Because mutations in Presenilins increase neuronal cell death,
our findings suggest that activation of cytosolic Omi/HtrA2 by
mutant Presenilins could be in part responsible for their in-
creased apoptotic activity.
EXPERIMENTAL PROCEDURES
Cell Culture—Cells were cultured either in Dulbecco’s modified Ea-
gle’s medium (DMEM) (HeLa and MEFs), DMEM/F-12 (293T cells), or
RPMI 1640 (MCF-7 cells), supplemented with 10% fetal bovine serum,
200 gml1 penicillin, and 100 gml1 streptomycin sulfate. MEFs
were isolated at E15 from mnd2/mnd2 embryos (20) and then immor-
talized by transfection with large T antigen cDNA. The human Omi/
HtrA2-expressing mnd2-Omi/HtrA2 MEFs were generated by stable
transfection of the immortalized mnd2 MEFs with a retroviral expres-
sion vector containing the full-length human Omi/HtrA2 cDNA (MSCV-
hOmi). The mnd2-vector cells were generated from the immortalized
mnd2 MEFs by stable transfection with the empty retroviral expression
vector MSCV. HeLa cells expressing C-terminal FLAG-tagged full-
length Omi/HtrA2 or only the PDZ domain of Omi/HtrA2 in the mito-
chondria were generated by stable transfection of HeLa Tet-OffTM (BD
Biosciences) with the expression plasmid pTRE2-Omi/HtrA2 or pTRE2-
Omi/HtrA2-MTS-PDZ, respectively.
Expression Constructs—Mammalian and bacterial expression con-
structs for WT and mutant Omi/HtrA2, -casein, XIAP, c-IAP1, and
c-IAP2 have been described previously (13, 17, 20). pTRE2-Omi/HtrA2
or pTRE2-Omi/HtrA2-MTS-PDZ were generated by inserting the
cDNAs of full-length human Omi/HtrA2 or its mitochondrial targeting
sequence fused in-frame to the PDZ domain, respectively, in the mul-
tiple cloning site of the expression plasmid pTRE2TM (BD Biosciences).
DegS-MA and RseA (residue 120 to end) were amplified by PCR using
genomic DNA from Escherichia coli as a template and cloned in-frame
into pET28a. The variants of GST having C-terminal tail of PS1 were
generated by PCR using appropriate primers and cloned into pET28a.
N-terminal GFP-tagged PS1 constructs were generated by PCR using
appropriate primers and cloned into pEGFP vector. The nucleotide
sequences of all constructs were confirmed by automated sequencing.
Peptide Synthesis—All peptides were synthesized by solid-phase
techniques using a Symphony Multiplex synthesizer (Protein Technol-
ogies, Inc., Tucson, AZ) or a 9050 Pepsynthesizer Plus automated pep-
tide synthesizer (Perseptive Biosystems, Cambridge, MA) withN-Fmoc/
tert-butyl chemistry. For this procedure, Fmoc amino acids (4
equivalents) were activated with a mixture of 1-hydroxybenzo-triazole/
2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexaflu-
orophosphate (4 equivalents each) and diisopropylethylamine (8 equiv-
alents) in dimethylformamide solvent. The Fmoc protecting group was
removed with 20% piperidine in dimethylformamide. Deprotection of
the amino acid side chains and cleavage of the peptide from the resin
was performed by a 2.5-h incubation of the peptide in a mixture con-
taining 95% trifluoroacetic acid, 2.5% water, and triisopropylsilane. For
peptides containing cysteine and/or methionine, the deprotection mix-
ture consisted of 94.5% trifluoroacetic acid, 2.5% water, 2.5% ethanedi-
thiol, and 1% triisopropylsilane. Peptides were purified by reverse-
phase high performance liquid chromatography (HPLC) on a C18 Vydac
column using the 0.1% trifluoroacetic acid solvent system (aqueous
buffer, 0.1% trifluoroacetic acid in HPLC grade H2O-organic phase,
0.1% trifluoroacetic acid in 90% acetonitrile). The peptides were char-
acterized by analytical HPLC and matrix-assisted laser desorption/
ionization time-of-flight mass spectrometry. All the peptides were at
least 95% pure, as determined by HPLC.
Transfections and Fluorescence Microscopy—Cells grown on 12-well
plates were transfected with the required plasmids. The transfections
were done using LipofectAMINE Plus reagent (Invitrogen) according to
the manufacturer’s instructions. All the plasmids for transfection were
prepared by using Qiagen columns. After 24–48 h of transfection, cells
were observed using fluorescence microscope.
Co-immunoprecipitation Assays—HeLa Tet-OffTM cells stably ex-
pressing FLAG-Omi/HtrA2 and FLAG-Omi/HtrA2-PDZ under the con-
trol of the Tet-Off system were induced for 48 h, in DMEM medium
without tetracycline. Cells were trypsinized, collected by centrifugation,
and washed three times with ice-cold PBS. Cells were resuspended in
PBS containing (1 mg/ml) dimethyl-3,3-dithiobispropionimidate2HCl
(DTBP) (protein cross-linker), diluted from freshly prepared stock so-
lution (50 mg/ml), and incubated at 4 °C for 2 h. Subsequently cells were
washed twice with PBS and resuspended in IP buffer (20 mM Tris, pH
7.5, 100 mM NaCl, 0.5% Nonidet P-40, 0.5 mM EDTA, 0.5 mM phenyl-
methylsulfonyl fluoride, and protease inhibitor mixture (Roche Applied
Science)). Cells were lysed by passing 30 times through a 23.5-gauge
needle and centrifuged at 14,000 rpm for 10 min. Cell lysates were
pre-cleared with protein G-Sepharose and incubated with FLAG anti-
body (1:200) at 4 °C for 4 h. The immunocomplexes were precipitated
and analyzed by Western blotting with PS1 antibody (Ab14) (kind gift
from Dr. Sam Gandy, Thomas Jefferson University, Philadelphia, PA).
In some experiments, 293T cells were co-transfected with constructs
encoding GFP or C-terminal GFP-tagged full-length PS1, and FLAG-
tagged mature Omi/HtrA2. 36 h after transfection, the cells were incu-
bated with the cross-linker DTBP and then lysed in IP buffer as above,
and the lysates were immunoprecipitated with an anti-GFP antibody.
The immunoprecipitates were fractionated by SDS-PAGE and Western
blotted with a FLAG antibody or an Omi/HtrA2-specific antibody. In
other experiments, endogenous PS1 was immunoprecipitated with the
PS1-Ab14 antibody from 293T cells after incubation with the cross-
linker DTBP, and the immunoprecipitates were Western blotted with
an Omi/HtrA2-specific antibody.
Cell Death Assays—Cells were seeded in 24-well plates at a density
of 2 104 cells per well and treated with PTD or PTD-PS1-C15 peptides
followed by staining with propidium iodide (PI). Cells showing PI stain-
ing, loss of cell volume, loss of refractility, and membrane blebbing were
scored as apoptotic. At least 200 cells were counted in each well. The
data represent mean  S.D. from at least three independent experi-
ments. Cell death induced by transient transfection of the GFP-tagged
PS1 constructs was determined as above.
RESULTS
Omi/HtrA2 Interacts with the C-terminal Tail of PS1—The 3-
to 4-residue PDZ bindingmotif located at the extremeC terminus
in bacterial outer membrane porins (OMP) is an important reg-
ulator of the enzymatic activity of the bacterial HtrA protease
DegS (28, 29). Because Omi/HtrA2 shares extensive sequence
and structural homology with DegS (28, 29), we reasoned that its
enzymatic activity might be regulated by a similar mechanism.
Computer searches for mammalian membrane proteins with
PDZ binding motifs similar to those present in the OMP proteins
identified PS1 and PS2, as likely regulators for the serine prote-
ase activity of Omi/HtrA2. To test this hypothesis, we examined
the ability of the last 15 residues of the cytoplasmic tail of PS1,
which contains a consensus PDZ binding motif (FYI-COOH), to
interact with Omi/HtrA2 by in vitro GST-pull-down assays. For
this purpose we generated variants of GST having residues from
the cytoplasmic tail of PS1 fused to the C terminus of GST (Fig.
1A). As shown in Fig. 1B, 15 residues of the C terminus of PS1
fused to GST (GST-PS1-C15) were able to precipitate endogenous
Omi/HtrA2 from 293T cell extracts. However, no interaction was
seen when the last 3 residues of PS1 were deleted (GST-PS1-
C3), or when only the last 3 residues of PS1 were used (GST-
PS1-C3). These results indicate that the C-terminal 15 residue
tail of PS1 interacts with Omi/HtrA2 and that the PDZ binding
motif and residues adjacent to it are required for this interaction.
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To further investigate the interaction between Omi/HtrA2
and PS1, in vivo, we performed co-immunoprecipitation assays.
For this purpose, we used HeLa cells stably expressing FLAG-
tagged Omi/HtrA2 and Omi/HtrA2-PDZ domains (Fig. 1C).
Endogenous PS1 was immunoprecipitated with the FLAG an-
tibody from both the full-length Omi/HtrA2- and Omi/HtrA2-
PDZ-expressing cells, but not the vector control (Fig. 1C). We
also co-transfected 293T cells with constructs encoding N-ter-
minal GFP-tagged full-length PS1 and FLAG-tagged mature
Omi/HtrA2. As predicted, the GFP-PS1 fusion protein was also
able to bind the ectopically expressed FLAG-tagged Omi/HtrA2
(Fig. 1D, fifth lane) and the endogenous Omi/HtrA2 (Fig. 1D,
second lane). Furthermore, we immunoprecipitated endoge-
nous PS1 from 293T cells with a PS1-specific antibody and
probed the immunoprecipitates with an Omi/HtrA2-specific an-
tibody (Fig. 1E). Endogenous Omi/HtrA2 was immunoprecipi-
tated with the PS1 antibody (fifth lane) but not with the non-
specific antibody (fourth lane), indicating that endogenous
Omi/HtrA2 interacts specifically with endogenous PS1. Com-
bined, these results demonstrate that PS1 does indeed interact
with Omi/HtrA2 via the PDZ domain.
C-terminal Presenilin Peptides Regulate Omi/HtrA2 Protease
Activity—Recent structural information suggests that the ac-
tive sites of Omi/HtrA2 and the bacterial homolog DegS are
present in a nonfunctional state when their PDZ domains are
not bound to the activation peptides (28). Binding of the acti-
vation peptides to the PDZ domain induces a conformational
change in the flexible L3 loop, which triggers reorientation of
the activation domain yielding a functional active site, thereby
promoting degradation of the substrates. To test whether the C
terminus of PS1 is an activation peptide for Omi/HtrA2, we
assayed the activity of purified mature Omi/HtrA2 with 35S--
casein and IAPs as substrates, in the presence or absence of a
peptide corresponding to the last 15 residues of the C terminus
of PS1 (PS-C15). As predicted the PS-C15 peptide drastically
increased the protease activity of Omi/HtrA2 toward these
FIG. 1. Interaction of Omi/HtrA2 with the C-terminal tail of PS1. A, schematic representation of various GST-PS1 fusion proteins having
PS1 residues fused at the C terminus of GST. B, in vitro interaction of Omi/HtrA2 with GST-PS1-C15 fusion protein. Extracts from 293T cells were
incubated with GST, GST-PS1-C3, GST-PS1-C3, or GST-PS1-C15 fusion protein immobilized on glutathione-Sepharose beads. The beads were
washed, and the bound proteins were eluted with SDS sample buffer and Western blotted with Omi/HtrA2-specific antibody. First lane, total
extracts from human 293T cells. C, in vivo interaction of Omi/HtrA2 and PS1. FLAG-tagged Omi/HtrA2 and Omi/HtrA2-PDZ domains were
immunoprecipitated from HeLa cells with anti-FLAG antibody after cross-linking the cells with 1 mg/ml DTBP.Upper panel, Western blot analysis
of immunoprecipitates with PS1 antibody. Lower panel, expression of PS1, FLAG-tagged proteins, and Omi/HtrA2 proteins in these cells. Note that
the expression of the Omi/HtrA2-PDZ domain is comparable to the expression of endogenous Omi/HtrA2 in HeLa cells. D, 293T cells were
transfected with the indicated constructs, and their lysates were then immunoprecipitated with anti-GFP antibody and Western blotted with
anti-FLAG (first panel from top) or anti-Omi/HtrA2 antibody (second panel from top). Note that the FLAG-tagged Omi/HtrA2 migrates slower than
the endogenous Omi/HtrA2 (Endo-Omi). The total cell lysates were Western blotted with anti-FLAG and anti-GFP antibodies as indicated. E,
lysates from 293T cells or control buffer were immunoprecipitated with the PS1-Ab-14 antibody or pre-immune serum as indicated. The
immunoprecipitates were fractionated and Western blotted with anti-Omi/HtrA2 antibody (upper panel) or PS1-Ab-14 antibody (lower panel). The
first lane shows total 293 cell lysates.
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substrates, indicating that binding of this peptide to the PDZ
domain could indeed modulate the protease activity of Omi/
HtrA2 (Fig. 2B).
The PDZ domains usually recognize 3–4 residue motifs that
occur at the C terminus of target proteins, although in some
rare cases specificity of recognition extends beyond 4 residues.
To determine the optimal number of amino acid residues re-
quired for recognition of Omi/HtrA2 PDZ domain, we used
peptides corresponding to the last 3, 8, and 15 residues of PS1
and its homolog PS2 (Fig. 2A). In addition, we also used
GQYYFV-COOH peptide, recently reported to bind Omi/HtrA2
PDZ domain and increase protease activity (30). As shown in
Fig. 2C, the 15-residue peptides patterned after PS1 and PS2
significantly increased the protease activity of Omi/HtrA2
against 35S--casein, whereas the 3-residue or 8-residue pep-
tides had no or slight effect, respectively (Fig. 2C). Surpris-
ingly, the previously described GQYYFV-COOH peptide
showed no effect on Omi/HtrA2 protease activity under these
conditions. Essentially similar results were obtained with
XIAP, c-IAP1, and c-IAP2 as substrates. The PS1-C15 pep-
tide had no enzymatic activity when assayed without Omi/
HtrA2 and had no effect on the activity of an Omi/HtrA2
mutant without PDZ domain (data not shown). Combined,
the above data indicate that the PDZ domain regulates Omi/
HtrA2 protease activity and that the 3-residue PDZ binding
motif in PS1 or PS2 is not sufficient for this effect but adja-
cent residues are required to relieve the inhibition of the PDZ
domain. Because there was no significant difference between
FIG. 2. Activation of Omi/HtrA2 protease activity by the C-terminal peptides of presenilins. A, sequences of the peptides designed from
the C termini of PS1 and PS2. B–D, in vitro translated 35S-labeled -casein, XIAP, c-IAP1, or c-IAP2 (2 l) was incubated with purified Omi/HtrA2
(5 M) protein in the presence (100 M) of the indicated peptides (B and C) or the indicated increasing concentrations of the PS1-C15 peptide (D)
for 30 min (for -casein) or 1 h (for IAPs) at 37 °C in a reaction volume of 30 l. The first lane in each panel is the buffer control. The reaction
products were analyzed by SDS-PAGE and autoradiography.
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the protease-promoting activity of PS1-C15 and PS2-C15
peptides, we decided to use the PS1-C15 peptide for further
studies.
To determine the effective concentration of the PS1 peptide,
we incubated Omi/HtrA2 together with substrates and increas-
ing concentrations of this peptide. PS1 peptide caused a dose-
dependent increase in Omi/HtrA2 protease activity toward
-casein, XIAP, c-IAP1, and c-IAP2 substrates (Fig. 2C). PS1
peptide showed a marked protease stimulatory activity at 10
M concentration. Similar concentrations of peptides were used
recently to demonstrate activation of DegS by OMP peptides
(28, 29).
To further investigate the activity of the last 15 residues of
PS1 in a context of a globular protein, we fused this peptide
or shorter variants of this peptide to the C terminus of GST
(Fig. 1B). Next we tested the effect of purified GST and the
GST-PS1 fusion variants on protease activity of Omi/HtrA2.
As shown in Fig. 3, GST protein having the last 15 amino acid
residues (GST-PS1-C15) of PS1 at its C terminus markedly
enhanced the protease activity of Omi/HtrA2. However, GST
or the GST variant with only the last 3 residues of PS1
(GST-PS1-C3) had no such effect on protease activity of Omi/
HtrA2. No effect was also seen with the GST-PS1-C3 vari-
ant, in which the 3-residue PDZ binding motif at the extreme
C terminus of the PS1 peptide is deleted (Fig. 3). Combined,
these results indicate that the last 3 amino acids in the PS1
peptide are important for interaction with the PDZ domain of
Omi/HtrA2, but adjacent residues are also required. Further-
more, the presence of the PS1 peptide in the context of a
globular protein such as GST does not affect their activity
toward Omi/HtrA2.
C-terminal Peptide of PS1 Activates DegS Protease Activity—
DegS is a bacterial trimeric serine protease related to Omi/
HtrA2. Binding of tripeptides derived from the C termini of
OMP proteins to the PDZ domain of DegS has been shown to
activate DegS protease activity (28, 29). This indicates that
both Omi/HtrA2 and DegS are activated by a similar mecha-
nism; binding of peptide ligands to the PDZ domain relieves the
inhibitory effect, resulting in activation of the protease domain.
If this is the case then the 15-residue PS1 peptide might also
activate DegS. To test this hypothesis we compared the activa-
tion of DegS protease activity by the OMP C-terminal tripep-
tide YYF-COOH and the PS1 C-terminal 15- or 3-residue pep-
tides. Surprisingly, the 15-residue PS1 peptide activated DegS
protease activity much more efficiently than the YYF-COOH
peptide, whereas 3-residue PS1 peptide had no effect (Fig. 4).
Similar results were obtained using RseA, a physiological sub-
strate of DegS and the nonphysiological substrate -casein.
However, DegS was unable to cleave IAPs under similar con-
ditions (Fig. 4) indicating that IAPs are specific substrates for
Omi/HtrA2. These results also suggest that the peptide recog-
nition site in the PDZ domains of DegS and Omi/HtrA2 are
evolutionarily conserved, a conclusion that is supported by
recent structural data (28). Nevertheless, the two proteases
differ in their responsiveness to tripeptides; whereas DegS
could be activated by tripeptides (29), neither the OMP (YYF-
COOH) nor the PS1 (FYI-COOH) C-terminal tripeptides were
able to activate Omi/HtrA2 under these conditions (Fig. 2C and
data not shown).
Cell-permeable Peptide Having C-terminal Residues of PS1
Induces Omi/HtrA2-dependent Cell Death—Next we decided to
examine the effect of Omi/HtrA2 activation by PS1-C15 peptide
FIG. 3. Effect of PS1 C-terminal peptides fused to the C termi-
nus of GST on Omi/HtrA2 protease activity. In vitro translated
35S-labeled -casein, XIAP, c-IAP1, and c-IAP2 (2 l) were incubated
with purified Omi/HtrA2 (5 M) protein in the absence () or presence
of GST (15 M) or the indicated GST-PS1 fusion proteins (15 M) for 30
min (for -casein) or 1 h (for IAPs) at 37 °C in a reaction volume of 30
l. The reaction products were analyzed by SDS-PAGE and autoradiog-
raphy. The indicated purified GST or GST-PS1 fusion proteins were
resolved by SDS-PAGE and stained by Coomassie Blue.
FIG. 4. Effect of C-terminal PS1 peptides on protease activity
of DegS. In vitro translated 35S-labeled RseA, -casein, XIAP, c-IAP1,
and c-IAP2 (2 l) were incubated with purified DegS protein (5 M) in
the presence of indicated peptides (100 M) for 16h at 37 °C in a reaction
volume of 30 l. The reaction products were analyzed by SDS-PAGE
and autoradiography.
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on the viability of mammalian cells. For this purpose we syn-
thesized 15-residue peptide corresponding to PS1 C terminus
fused to the C terminus of the protein transduction domain of
antennapedia (PTD-PS1-C15) and control peptide having
only the protein transduction domain of antennapedia (PTD)
(Fig. 5A). The PTD allows the hybrid peptides to cross the cell
membrane. Once inside the cell they could enter the mito-
chondria because of their small size, because the mitochon-
drial outer membrane is permeable to molecules of 6 kDa or
less (31). First, we checked the activation of Omi/HtrA2 pro-
tease activity by PTD-PS1-C15 and PTD in vitro. The PTD-
PS-C15 peptide activated Omi/HtrA2 protease activity,
whereas the PTD peptide did not show any activation under
similar conditions (data not shown). When 293T or MCF-7
cells were treated with the PTD or the PTD-PS1-C15, the
PTD-PS1-C15 peptide induced substantial cell death in both
293T and MCF-7 cells as depicted by the increase in pro-
pidium iodide (PI)-positive cells (Fig. 5, B and C). However,
PTD-treated cells showed no significant difference from con-
trol untreated cells (Fig. 5, B and C). In addition treatment of
293T and MCF-7 cells with 15-residue PS1 peptide lacking
protein transduction domain had no effect on cell viability
(data not shown).
In the mnd2 mouse the protease activity of Omi/HtrA2 is
abolished by a missense mutation, which changes a conserved
serine at position 276 to cysteine (20). To determine the role of
Omi/HtrA2 in PTD-PS1-C15 peptide-induced cell death, we
generated isogenic cell lines differing only in the Omi/HtrA2-
function from mnd2 mouse embryonic fibroblasts (MEFs). For
this purpose we immortalized mnd2 MEFs, which lack Omi/
HtrA2 activity, and then stably transfected the immortalized
mnd2 MEFs with an empty vector control or a vector express-
ing human Omi/HtrA2. The expression of Omi/HtrA2 was
confirmed both by degradation of 35S-labeled -casein by
immunoprecipitated Omi/HtrA2 from the mnd2-Omi/HtrA2
cells but not the mnd2-vector cells (Fig. 6A) and by Western
blot analysis (Fig. 6B). mnd2-vector and mnd2-Omi/HtrA2
cells were treated with PTD (50 M) and PTD-PS1-C15 (50
M) and subsequently stained with PI. The proportion of
PI-positive cells was significantly higher in mnd2-Omi/HtrA2
cells after treatment with the PTD-PS1-C15 peptide com-
pared with untreated control cells or cells treated with the
PTD peptide (Fig. 6C). However, there was only a slight
increase in the number of PI-stained cells in the mnd2-vector
cells after treatment with the PTD-PS peptide (Fig. 6C). The
PTD-PS1-C15 peptide induced 50% cell death in mnd2-
Omi/HtrA2 cells and 15% cell death in mnd2-vector cells
(Fig. 6D). Cell death induced by the PTD-PS1-C15 peptide
was not inhibited by the pan-caspase inhibitor z-VAD-fmk in
both vector and Omi/HtrA2-expressing cells. This difference
in cell death was not due to compromised cell death machin-
ery in mnd2-vector cells, because the percentage of cell death
in the mnd2-vector cells was similar to that in the mnd2-Omi/
HtrA2 cells upon treatment with tunicamycin or 5-fluoroura-
cil (data not shown).
Earlier we have shown that deletion of the PDZ domain
partially restores protease activity to the S276C mutant Omi/
HtrA2. Thus, we decided to examine whether the 15-residue
PS1 peptide can also restore protease activity to the S276C
mutant Omi/HtrA2. As shown in Fig. 6E, the 15-residue PS1
peptide partially restored the protease activity to the S276C
mutant Omi/HtrA2 (fifth lane), but had no effect on the activity
of the S276C Omi/HtrA2-PDZ mutant, which lacks the PDZ
domain (seventh lane). These data provide further proof that
the PS1 peptide modulates the activity of Omi/HtrA2 by im-
pacting its PDZ domain. Nevertheless, the activation of the
protease activity of the S276C mutant Omi/HtrA2 by the PS1
peptide was significantly less than that of the wild type Omi/
HtrA2 (third lane). This difference in potentiation of protease
activity correlates well with the difference in cell death be-
tween mnd2-vector and mnd2-Omi/HtrA2 cells after treatment
with the PTD-PS1-C15 peptide (Fig. 6, C and D). These results
suggest that constitutive activation of the Omi/HtrA2 protease
in the mitochondria by the PTD-PS1-C15 peptide leads to
cell death.
PS1 Augments Omi/HtrA2-induced Cell Death—During apo-
ptosis Omi/HtrA2 is released from mitochondria to the cyto-
FIG. 5. Effect of PS1 peptide fused to protein transduction
domain of antennapedia on cell viability. A, sequence of protein
transduction domain of antennapedia (PTD) and PS1 peptide fused to
PTD of antennapedia (PTD-PS1-C15). B, 293T and MCF-7 cells were
treated with vehicle (Me2SO (DMSO)), PTD, or PTD-PS1-C15 peptides
at 50 M and 25 M, respectively, and then stained with propidium
iodide. The percentage of cell death was determined as described under
“Experimental Procedures.” C, representative fields of Me2SO-treated
(DMSO), PTD-treated (PTD), and PTD-PS1-C15-treated (PTD-PS1-
C15) cells. Cells were visualized by fluorescence microscopy (10).
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plasm where it binds to inhibitor of apoptosis proteins (IAPs)
and cleave IAPs in the cytoplasm (17, 18). To determine the
effect of ectopic expression of PS1 on Omi/HtrA2-induced cell
death, we co-expressed full-length PS1 or PS1 lacking the
last three C-terminal residues together with mature wild-
type or a catalytically inactive (S306A) Omi/HtrA2 in MCF-7
cells. As shown in Fig. 7A, expression of mature wild-type
Omi/HtrA2 in MCF-7 cells induced significant apoptosis,
which was further enhanced by co-expression of full-length
PS1, but not PS1 lacking the PDZ binding motif. The cata-
lytically inactive mutant Omi/HtrA2 did not show any signif-
icant cell death in the presence or absence of ectopic PS1 (Fig.
7A). Consistent with these results we also found that ectopic
expression of wild-type Omi induces less cell death in PS1-
deficient or PS1- and PS2-deficient MEFs compared with
wild-type MEFs (Fig. 7B). These results indicate that PS1
can increase Omi/HtrA2-mediated cell death by enhancing its
protease activity in the cytosol. In addition, the ability of PS1
to enhance Omi/HtrA2-induced cell death was dependent on
its PDZ binding motif.
Expression of Mutant PS1 Induces Omi/HtrA2-dependent
Cell Death—Neuronal apoptosis has been implicated in Alzhei-
mer disease and mutations in PS may predispose neurons to
apoptotic cell death. It has been previously demonstrated that
expression of the Alzheimer mutant PS1 (M146V and L286V)
sensitizes PC12 cells to amyloid- and trophic factor with-
drawal induced cell death (32). We evaluated the effect of
mutant PS1 (M146V and L286V missense mutations) on cell
viability. First, we compared the apoptotic activity of full-
length wild-type and M146V mutant PS1 with or without the
PDZ binding motif. As shown in Fig. 8A, expression of the
full-length M146V mutant PS1 induced significantly more cell
FIG. 6. Role of Omi/HtrA2 in PS1
peptide-induced cell death. A, Omi/
HtrA2 protein was immunoprecipitated
from mnd2-vector, mnd2-Omi/HtrA2, and
293T cells and assayed with in vitro
translated 35S-labeled -casein. The reac-
tion products were analyzed by SDS-
PAGE and autoradiography. B, Western
blots of whole cell lysates from mnd2-vec-
tor, mnd2-Omi/HtrA2, 293T, and MCF-7
cells with Omi/HtrA2 and GAPDH anti-
bodies. The Omi/HtrA2 antibody was
raised against human Omi/HtrA2 but can
also detect mouse Omi/HtrA2 to a lesser
extent. C, mnd2-vector and mnd2-Omi/
HtrA2 cells were treated with vehicle
(Me2SO (DMSO)), PTD, or PTD-PS1-C15
(50 M) peptides in the absence or presence
of the pan-caspase inhibitor z-VAD-fmk (50
M). Cells were visualized by fluorescence
microscopy (10). Representative fields of
control Me2SO-treated (DMSO), PTD-
treated (PTD), PTD-PS1-C15-treated (PTD-
PS1-C15) and PTD-PS1-C15 plus zVAD-
fmk-treated (PTD-PS1-C15z-VAD-fmk)
cells. D, cells were treated as in C, and then
the percentage of cell death was determined
as described under “Experimental Proce-
dures.” E, in vitro translated 35S-labeled ca-
sein was incubated with equal amounts (5
M) of purified wild type Omi/HtrA2 (Omi/
HtrA2-WT), S276C mutant Omi/HtrA2
(Omi/HtrA2-S276C), or S276C mutant Omi/
HtrA2 PDZ (Omi/HtrA2-S276C PDZ)
protein in the absence or presence of the
15-residue PS1 peptide PS1-C15 (100 M)
for 30 min at 37 °C. The reaction products
were analyzed by SDS-PAGE and autora-
diography. The indicated purified Omi/
HtrA2 proteinswere resolved by SDS-PAGE
and stained by Coomassie Blue.
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death than the wild-type PS1. However, very little difference
was observed between the wild-type and M146V mutant PS1
constructs without the PDZ binding motif (Fig. 8A). These
results indicate that the PDZ binding motif of PS1 contributes
to its apoptotic activity.
Next we determined the role of Omi/HtrA2 in the Alzheimer
mutant PS1-induced cell death. For this purpose, mnd2-Omi/
HtrA2 and mnd2-vector cells were transfected with wild-type
and mutant (M146V and L286V) PS1 with or without the PDZ
binding motif. Expression of mutant PS1 (M146V and L286V)
induced substantially more cell death in mnd2-Omi/HtrA2 cells
as compared with mnd2-vector cells (Fig. 8B). However, there
was little difference in cell death induced by mutant PS1
(M146V and L286V) without the PDZ binding motif, in mnd2-
Omi/HtrA2 and mnd2-vector cells (Fig. 8B). These results sug-
gest that mutant PS1 induces cell death in Omi/HtrA2-depend-
ent and -independent fashions. However, the PDZ binding
motif of PS1 appears to be required for Omi/HtrA2-dependent
cell death.
DISCUSSION
Omi/HtrA2 is a member of the HtrA serine protease family,
which contains a central trypsin-like protease domain followed
by one or two C-terminal regulatory PDZ domains (21). The
functional unit of Omi/HtrA2 is a homotrimer, which is formed
by three monomers of Omi/HtrA2 packed symmetrically to
create a funnel-like structure with the protease domains form-
ing the core of the molecule and the PDZ domains protruding
outwards (33). The active sites of the protease are located on
the concave side of the funnel. Recent structural data (28)
indicate that the PDZ domain of Omi/HtrA2 might function
similarly as in DegS, to regulate the catalytic activity of the
protease domain. In the unbound state, the PDZ domain is
tethered by multiple interactions to the protease domain trap-
ping the flexible L3 loop and the so-called “activation domain,”
which is formed by loops L1, L2, and LD in an inactive confor-
mation. Upon binding of the PDZ domain to specific activation
peptides in target proteins, it releases the flexible L3 loop,
which in turn triggers reorientation of the activation domain
resulting in increased protease activity. So far, there are no
known physiological activation peptides for the PDZ domain of
Omi/HtrA2. In this study we demonstrated that the C terminus
of Presenilin contains a PDZ binding motif, which functions as
a physiological activation peptide for the PDZ domain of Omi/
HtrA2. Our results suggest that the C-terminal PDZ binding
motif of PS1 interacts with the PDZ domain of Omi/HtrA2 and
relieves its inhibition of the protease domain resulting in in-
creased protease activity toward IAPs and -casein (Fig. 2).
These results demonstrate that the PDZ binding motif of PS1
functions similarly as in the OMP proteins to modulate the
protease activity of Omi/HtrA2.
The first identified and the most important function of PDZ
domains is the recognition of specific C-terminal PDZ binding
motifs found in target proteins, most often in the cytoplasmic
tails of transmembrane receptors and channels (34, 35). Our
results demonstrated that the conserved PDZ binding motif
(FYI-COOH) in the C-terminal tail of PS1 is critical for binding
to Omi/HtrA2. Substituting the C-terminal isoleucine with gly-
cine or deleting this motif abolished binding to Omi/HtrA2 and
the effect on Omi/HtrA2 protease activity (Figs. 1 and 3, and
data not shown). However, the effect on Omi/HtrA2 activity
requires more than the canonical X-COOH PDZ binding
motif. Our data demonstrated that the PS1 FYI-COOH peptide
is not sufficient for activation of Omi/HtrA2, suggesting that
specific residues as far back as15 appear to be involved in the
interaction between the PDZ domain of Omi/HtrA2 and the C
terminus of presenilins (Fig. 2C). The involvement of residues
upstream of the C-terminal tripeptide in PDZ recognition has
also been reported for interactions between CRIPT postsynap-
tic protein and the third PDZ domain of PSD-95/SAP90 (36),
and between muscle sodium channels and the syntrophin PDZ
domain (37, 38).
Recently, Martins et al. (30) described a synthetic six-residue
optimal Omi/HtrA2 PDZ domain-binding peptide (GQYYFV-
COOH), which could increase Omi/HtrA2 activity toward a
synthetic octapeptide substrate. However, in our hands the
same GQYYFV-COOH hexapeptide was not effective with -ca-
sein or IAPs as substrates (Fig. 2C). This suggest that binding
of short peptides such as the GQYYFV-COOH to the PDZ
domain of Omi/HtrA2 does not trigger complete conformational
changes in the L3 loop and the adjacent activation domain to
allow binding of large protein substrates to the active site
pocket. Longer peptides, such as the 15-residue PS1 peptide
described here, might be required to trigger complete reorien-
FIG. 7. Presenilins augments Omi/HtrA2-induced cell death. A,
MCF-7 cells were transiently transfected with vector control, wild-type
mature Omi/HtrA2, or S306A mature Omi/HtrA2 constructs together
with GFP (C), or N-terminal GFP-tagged wild-type PS1-FL (PS1-FL) or
wild-type PS1-C3 (PS1-C3) constructs as indicated. After 24 h of
transfection the percentage of cell death was determined as described
under “Experimental Procedures.” B, wild-type (WT), PS1-knockout
(PS1 /), or PS1 and PS2 double-knockout (PS1/PS2 /) MEFs
were transfected with vector control, wild-type mature Omi/HtrA2, or
S306A mature Omi/HtrA2 constructs together with GFP. After 16 h of
transfection, the percentage of cell death (upper panel) was determined
as described under “Experimental Procedures.” The expression of the
transfected Omi/HtrA2 proteins is shown in the lower panel.
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tation of the L3 loop and the adjacent activation domain and
maintain a functional active site, which allows access or bind-
ing of large protein substrates to the active site pocket. It is also
possible that the length of the peptide is not the determining
factor in triggering Omi/HtrA2 activation but that specific res-
idues N-terminal to the 3- to 4-residue PDZ binding motif in the
15-residue PS1 peptide might be required to trigger complete
conformational changes.
The structure of Omi/HtrA2 is similar to that of the bacterial
HtrA protease DegS, which has been shown to protect against
environmental stresses by acting as a sensor for unfolding
stresses (29). In E. coli, stress-induced accumulation of mis-
folded and unfolding outer membrane porins (OMPs) in the
periplasm is believed to expose their C-terminal PDZ binding
motifs, which bind the PDZ domain of DegS (28, 29). This
binding relieves the inhibitory interactions between the PDZ
and protease domains of DegS resulting in activation of its
proteolytic activity. The activated DegS cleaves and destroys
the transcription factor E-inhibitory protein RseA. The free E
then induces the E-dependent transcription of stress-respon-
sive genes.
In mammalian cells, exposure of mitochondria to stress could
also lead to accumulation of misfolded and unfolded proteins in
the intermembrane space, which might be sensed by Omi/
HtrA2, thereby triggering an Omi/HtrA2-specific stress re-
sponse pathway. Consistent with this hypothesis, Omi/HtrA2
was found to be essential for survival (20). The loss of Omi/
HtrA2 protease activity in mice is responsible for the increased
susceptibility of mnd2 mitochondria to induction of the perme-
ability transition and mitochondrial dysfunction (20), perhaps
due to a defect in sensing and responding to mitochondrial
folding stresses. Considering this important role of Omi/HtrA2
in maintenance of healthy mitochondria, its activity is probably
regulated by a mechanism similar to the mechanism that reg-
ulates DegS activity in bacteria.
FIG. 8. Mutant PS1 induces Omi/
HtrA2-dependent cell death. A, 293T
cells were transiently transfected with
GFP (C), N-terminal GFP-tagged wild-
type PS1-FL (PS1-WT-FL), mutant
M146V PS1-FL (PS1-M146V-FL), or their
corresponding C3 (lacking the PDZ
binding motif) constructs as indicated. Af-
ter 48 h of transfection the percentage of
cell death (upper panel) was determined
as described under “Experimental Proce-
dures.” The expression of the transfected
proteins is shown in the lower panel. B,
mnd2-Omi/HtrA2 and mnd2-vector cells
were transiently transfected with the in-
dicated constructs as in A. After 48 h of
transfection the percentage of cell death
was determined as described under “Ex-
perimental Procedures.”
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PS1, primarily located in the endoplasmic reticulum and cell
membranes, has also been recently found by subcellular frac-
tionation and immuno-electron microscopy in rat mitochon-
drial membranes and proposed to be part of the mitochondrial
megapore complex (39). We also found PS1 in the mitochon-
drial membranes of human cells (data not shown). The pres-
ence of PS1 in the mitochondrial membranes raises an inter-
esting possibility that PS1 might have a similar role in the
mitochondria analogous to the role of OMP proteins in bacteria.
During mitochondrial stress unfolded PS1 might accumulate in
the mitochondria and trigger activation of Omi/HtrA2 via its
PDZ binding motif. The activated Omi/HtrA2 in turn recog-
nizes and degrades specific mitochondrial substrates. The deg-
radation of these substrates might be required to induce stress-
responsive genes in the mitochondria to prevent accumulation
of damaged or misfolded proteins. However, more analysis is
required to determine the topology of PS1 in the mitochondrial
membranes and whether mitochondrial stress induces accumu-
lation of PS1 in the mitochondria.
Presenilins are expressed in neurons throughout the brain
and appear to be present in both degenerating and nondegen-
erating neurons in AD brain. It is interesting that the muta-
tions in presenilins identified in patients with familial AD are
missense mutations or in-frame deletions that do not truncate
the protein (40). The mechanisms by which these mutations
promote neuron degeneration in AD are not fully understood,
but it is possible that they may cause misfolding or significant
conformational changes in Presenilins, which increase cellular
stress. Consistent with this hypothesis, Presenilin mutations
appear to increase neuronal cell death by increasing oxidative
stress and accumulation and oligomerization of amyloid  (32).
These changes are thought to play a central role in the patho-
genesis of this disease by probably directly leading to mitochon-
drial dysfunction (41). Indeed, mitochondrial impairment, in-
cluding mitochondrial membrane depolarization, has been
documented in brain tissues from AD patients and in fibro-
blasts from patients harboring PS1 mutations (42). These mito-
chondrial alterations could therefore lead to release of Omi/
HtrA2 together with other inducers of cell death into the
cytoplasmwhere it binds to the C-terminal tail of themutant PS1
and becomes active. Activation of Omi/HtrA2 might in turn con-
tribute to cytoplasmic activation of apoptosis by direct degrada-
tion of IAPs and other unknown cellular substrates. Indeed, our
results indicate that full-length AD mutant PS1 proteins induce
more cell death in Om/HtrA2-containing cells than in Omi/
HtrA2-deficient cells. Thus, mutant presenilins could act as both
the inducers and enhancers of cell death in AD.
Another potential mechanism that might contribute to neu-
ronal cell death would be conformational changes in the mu-
tant presenilin protein that leads to accumulation of mutant
PS1 in the mitochondria and increased interaction of mutant
PS1 with the PDZ domain of Omi/HtrA2. The increased inter-
action between mutant presenilins and Omi/HtrA2 might con-
tribute to mitochondrial dysfunction by inducing prolonged
activation (overactivation) of Omi/HtrA2. Indeed, overactiva-
tion of Omi/HtrA2 protease activity using a cell-permeable
peptide having C terminus residues of PS1 induced potent
Omi/HtrA2-dependent cell death (Figs. 5 and 6). This corrobo-
rates the fact that all our attempts to obtain stable clones of
constitutively active Omi/HtrA2 (Omi/HtrA2 PDZ) have
failed.2 Therefore, based on our recent observations that
inactivation of Omi/HtrA2 in the mitochondria causes in-
creased cell death in mnd2 mice (20) and our present observa-
tions that overactivation of Omi/HtrA2 in the mitochondria
also causes cell death, we suggest that the activity of Omi/
HtrA2 is critically regulated and either loss of activity or excess
activity causes mitochondrial dysfunction leading to
neurodegeneration.
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